PharmacoEconomics - Open

2017 - 2025

Current editor(s): Timothy Wrightson and Christopher Carswell

From Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().

Access Statistics for this journal.
Is something missing from the series or not right? See the RePEc data check for the archive and series.

Volume 6, issue 6, 2022

Cost-Effectiveness Analyses of Lung Cancer Screening Using Low-Dose Computed Tomography: A Systematic Review Assessing Strategy Comparison and Risk Stratification pp. 773-786

Matthew Fabbro, Kirah Hahn, Olivia Novaes, Mícheál Ó’Grálaigh and James F. O’Mahony

The Cost of Flexible Bronchoscopes: A Systematic Review and Meta-analysis pp. 787-797

Carina Østervig Andersen, Helena Travis, Emilie Dehlholm-Lambertsen, Rasmus Russell and Emmelie Ploug Jørgensen

Implications of Payment for Acute Myocardial Infarctions as a 90-Day Bundled Single Episode of Care: A Cost of Illness Analysis pp. 799-809

Keith B. Allen, James E. Alexander, Joshua N. Liberman and Susan Gabriel

Cost-Effectiveness Analysis of Olaparib in Combination with Bevacizumab Compared with Bevacizumab Monotherapy for the First-Line Maintenance Treatment of Homologous Recombination Deficiency-Positive Advanced Ovarian Cancer pp. 811-822

David Elsea, Lin Fan, Adela Mihai, Fadoua El Moustaid, Daniel Simmons, Matthew Monberg and Dominic Muston

An EQ-5D-5L Value Set for Belgium pp. 823-836

Nicolas Bouckaert, Irina Cleemput, Stephan Devriese and Sophie Gerkens

Cost Effectiveness of Tofacitinib for the Treatment of Moderate to Severe Active Ulcerative Colitis in Colombia pp. 837-846

Fabio Gil, Fabian Juliao-Baños, Luisa Amador, Natalia Castano and Juan Manuel Reyes

What is the Economic Cost of Providing an All Wales Postpartum Haemorrhage Quality Improvement Initiative (OBS Cymru)? A Cost-Consequences Comparison with Standard Care pp. 847-857

Megan Dale, Sarah F Bell, Susan O’Connell, Cerys Scarr, Kathryn James, Miriam John, Rachel E Collis, Peter W Collins and Grace Carolan-Rees

Cost-Effectiveness Analysis of Ofatumumab for the Treatment of Relapsing-Remitting Multiple Sclerosis in Canada pp. 859-870

Moogeh Baharnoori, Virender Bhan, Fraser Clift, Kimberly Thomas, Soukaïna Mouallif, Nicholas Adlard, Philip Cooney, François Blanchette, Barkha P. Patel and Daniel Grima

Healthcare Costs Among Patients with Psoriasis Treated with Ixekizumab Versus Secukinumab in Real-World Settings Over 24 Months pp. 871-880

Andrew Blauvelt, Nianwen Shi, Russel Burge, Bilal Atiya, Baojin Zhu, Najwa Somani, Terri Ridenour, Carolyn R. Lew, Nicole M. Zimmerman and Mwangi J. Murage

Brentuximab Vedotin Plus CHP in Frontline sALCL: Adjusted Estimates of Efficacy and Cost-Effectiveness Removing the Effects of Re-Treatment with Brentuximab Vedotin pp. 881-892

Holly Cranmer, David Trueman, Elise Evers, Fionn Woodcock and Tanja Podkonjak

Should Drug Companies Engage with ICER? An Empirical Analysis of How Often Manufacturers Engage with ICER and Whether Engagement May Influence ICER’s Cost-Effectiveness Estimates pp. 893-895

Rachel Milstein Breslau, Joshua T. Cohen, Daniel A. Ollendorf and Peter J. Neumann

Correction to: Implications of Payment for Acute Myocardial Infarctions as a 90-Day Bundled Single Episode of Care: A Cost of Illness Analysis pp. 897-897

Keith B. Allen, James E. Alexander, Joshua N. Liberman and Susan Gabriel

Correction to: Cost-Effectiveness Analysis of Olaparib in Combination with Bevacizumab Compared with Bevacizumab Monotherapy for the First-Line Maintenance Treatment of Homologous Recombination Deficiency-Positive Advanced Ovarian Cancer pp. 899-899

David Elsea, Lin Fan, Adela Mihai, Fadoua El Moustaid, Daniel Simmons, Matthew Monberg and Dominic Muston

Volume 6, issue 5, 2022

Using Health Economics to Inform Immunization Policy Across All Levels of Government pp. 631-635

Ellen Rafferty, Laura Reifferscheid, Ali Assi and Shannon E. MacDonald

How are Companion Diagnostics Considered in Economic Evaluations of Oncology Treatments? A Review of Health Technology Assessments pp. 637-646

Melissa Gomez Montero, Houcine El Alili, Mahmoud Hashim, Peter Wigfield, Mariya Dimova, Ralph Riley and Katie Pascoe

Cost-Effectiveness of Nintedanib for Patients with Progressive Fibrosing Interstitial Lung Disease (PF-ILD) pp. 647-656

Lotte Westerink, Jelmer Lennart Jens Nicolai, Maarten Jacobus Postma, Job Frank Martien Boven and Cornelis Boersma

Cost-Utility and Budget Impact Analysis of Implementing Anticoagulation Clinics and Point-of-Care Monitoring Devices in Anticoagulated Patients in Argentina pp. 657-668

Osvaldo Ulises Garay, Gonzalo Guiñazú, Yolanda Patricia Adamczuk and Cristina Duboscq

Public Preferences and Willingness to Pay for a COVID-19 Vaccine in Iran: A Discrete Choice Experiment pp. 669-679

Alireza Darrudi, Rajabali Daroudi, Masud Yunesian and Ali Akbari Sari

Cost-Effectiveness Analysis of a Medial Meniscus Replacement Prosthesis for the Treatment of Patients with Medial Compartment Pain in the United Kingdom pp. 681-696

Mehdi Javanbakht, Atefeh Mashayekhi, Angeline Carlson, Eoin Moloney, Martyn Snow, James Murray and Tim Spalding

Cost-Utility of Nivolumab Plus Ipilimumab in First-Line Treatment of Advanced Melanoma in the United States: An Analysis Using Long-Term Overall Survival Data from Checkmate 067 pp. 697-710

Timothy Baker, Helen Johnson, Srividya Kotapati, Andriy Moshyk, Melissa Hamilton, Murat Kurt and Victoria Federico Paly

The Physician and Administrator-Reported Cost of Drug Utilization Management to Physician Practices: A Cross-Sectional Survey pp. 711-721

Marie Louise Edwards, Perry T. Yin, Michael Kuehn, Keith Bratti, Noam Kirson, Anupam Jena and Scott Howell

Cost-Utility Analysis of Planned Early Delivery or Expectant Management for Late Preterm Pre-eclampsia (PHOENIX) pp. 723-733

Rachael Hunter, Alice Beardmore-Gray, Melanie Greenland, Louise Linsell, Edmund Juszczak, Pollyanna Hardy, Anna Placzek, Andrew Shennan, Neil Marlow and Lucy C. Chappell

Budget Impact of Intravenous Iron Therapy with Ferric Carboxymaltose in Patients with Chronic Heart Failure with Reduced Ejection Fraction (HFrEF) and Iron Deficiency in Switzerland pp. 735-743

Elisabeth Brock, Giorgio Moschovitis, Micha T. Maeder and Otmar Pfister

Cost of Surgical Care at Public Sector District Hospitals in India: Implications for Universal Health Coverage and Publicly Financed Health Insurance Schemes pp. 745-756

Maninder Pal Singh, Shankar Prinja, Kavitha Rajsekar, Praveen Gedam, Vipul Aggarwal, Oshima Sachin, Jyotsna Naik, Ajai Agarwal, Sanjay Kumar, Setu Sinha, Varsha Singh, Prakash Patel, Amit C. Patel, Rajendra Joshi, Avijit Hazra, Raghunath Misra, Divya Mehrotra, Sashi Bhusan Biswal, Ankita Panigrahy, Kusum Lata Gaur, Jai Prakash Pankaj, Dharmesh Kumar Sharma, Kondeti Madhavi, Pulaganti Madhusudana, K. Narayanasamy, A. Chitra, Gajanan D. Velhal, Amit S. Bhondve, Rakesh Bahl, Amit Sachdeva, Sharminder Kaur, Anu Nagar and Balram Bhargava

The Cost Effectiveness of Patiromer for the Treatment of Hyperkalaemia in Patients with Chronic Kidney Disease with and without Heart Failure in Ireland pp. 757-771

Thomas Ward, Tray Brown, Ruth D. Lewis, Melodi Kosaner Kliess, Antonio Ramirez Arellano and Carol M. Quinn

Volume 6, issue 4, 2022

Medical and Non-medical Costs of Sickle Cell Disease and Treatments from a US Perspective: A Systematic Review and Landscape Analysis pp. 469-481

Zachary Baldwin, Boshen Jiao, Anirban Basu, Joshua Roth, M. A. Bender, Zizi Elsisi, Kate M. Johnson, Emma Cousin, Scott D. Ramsey and Beth Devine

Cost Effectiveness of Patient Self-Managed Warfarin Compared with Direct Oral Anticoagulants in Atrial Fibrillation: An Economic Evaluation in a Danish Healthcare Sector Setting pp. 483-494

Sabine Michelsen Raunbak, Anne Sig Sørensen, Louise Hansen, Flemming Skjøth, Torben Bjerregaard Larsen and Lars Holger Ehlers

Costs and Effects of Implementing Digital Tomosynthesis in a Population-Based Breast Cancer Screening Program: Predictions Using Results from the To-Be Trial in Norway pp. 495-507

Tron Anders Moger, Åsne Holen, Berit Hanestad and Solveig Hofvind

Direct Medical Costs of Four Vaccine-Preventable Infectious Diseases in Older Adults in Spain pp. 509-518

Ángel Gil de Miguel, José María Eiros Bouza, Luis Ignacio Martínez Alcorta, Daniel Callejo, Carlos Miñarro, Laura Amanda Vallejo-Aparicio, Andrea García, Mónica Tafalla, María del Rosario Cambronero, Rubén Rodríguez and Laura Martin-Gomez

Cost Effectiveness of Subcutaneous Vedolizumab for Maintenance Treatment of Ulcerative Colitis in Canada pp. 519-537

Elisabetta Fenu, Vasily Lukyanov, Annabel Acs, Xenia Radu, Stephanie Stypa, Aren Fischer, John K. Marshall and Mark Oppe

Differences in Breast Cancer Costs by Cancer Stage and Biomarker Subtype in New Zealand pp. 539-548

Chunhuan Lao, Mohana Mondal, Marion Kuper-Hommel, Ian Campbell and Ross Lawrenson

Cost-Effectiveness Analysis of Intravascular Targeted Temperature Management after Cardiac Arrest in England pp. 549-562

Mehdi Javanbakht, Atefeh Mashayekhi, Mohsen Rezaei Hemami, Michael Branagan-Harris, Thomas R Keeble and Mohsen Yaghoubi

Development of the Hypertrophic Cardiomyopathy Symptom Questionnaire (HCMSQ): A New Patient-Reported Outcome (PRO) Instrument pp. 563-574

Matthew Reaney, Veleka Allen, Amy J. Sehnert, Liang Fang, Albert A. Hagège, Srihari S. Naidu and Iacopo Olivotto

Longitudinal Psychometric Analysis of the Hypertrophic Cardiomyopathy Symptom Questionnaire (HCMSQ) Using Outcomes from the Phase III EXPLORER-HCM Trial pp. 575-586

Matthew Reaney, Prithvi Addepalli, Veleka Allen, John A. Spertus, Chantal Dolan, Amy J. Sehnert and Jennifer T. Fine

Cost Analysis of Adjuvant Whole-Brain Radiotherapy Treatment Versus No Whole-Brain Radiotherapy After Stereotactic Radiosurgery and/or Surgery Among Adults with One to Three Melanoma Brain Metastases: Results from a Randomized Trial pp. 587-594

Anh Dam Tran, Angela M. Hong, Mai T. H. Nguyen, Gerald Fogarty, Victoria Steel, Elizabeth Paton and Rachael L. Morton

Feasibility of Deriving Health State Utilities in Mycosis Fungoides Cutaneous T-Cell Lymphoma Using Mapping Algorithms pp. 595-603

Michela Meregaglia and Rosanna Tarricone

Economic Evaluation of Using Daily Prednisolone versus Placebo at the Time of an Upper Respiratory Tract Infection for the Management of Children with Steroid-Sensitive Nephrotic Syndrome: A Model-Based Analysis pp. 605-617

Nafsika Afentou, Emma Frew, Samir Mehta, Natalie J. Ives, Rebecca L. Woolley, Elizabeth A. Brettell, Adam R. Khan, David V. Milford, Detlef Bockenhauer, Moin A. Saleem, Angela S. Hall, Ania Koziell, Heather Maxwell, Shivaram Hegde, Eric Finlay, Rodney D. Gilbert, Caroline Jones, Karl McKeever, Wendy Cook, Nicholas J. A. Webb and Martin T. Christian

Healthcare Resource Utilization and Cost of Patients with Multiple Myeloma in Germany: A Retrospective Claims Data Analysis pp. 619-628

Zeki Kocaata, Thomas Wilke, Franz Fischer, Robert Welte and Hermann Einsele

Correction to: Similarities and Differences in Health Technology Assessment Systems and Implications for Coverage Decisions: Evidence from 32 Countries pp. 629-629

Anna-Maria Fontrier, Erica Visintin and Panos Kanavos

Volume 6, issue 3, 2022

Similarities and Differences in Health Technology Assessment Systems and Implications for Coverage Decisions: Evidence from 32 Countries pp. 315-328

Anna-Maria Fontrier, Erica Visintin and Panos Kanavos

Community Distribution of Naloxone: A Systematic Review of Economic Evaluations pp. 329-342

Nelda Cherrier, Joanne Kearon, Robin Tetreault, Sophiya Garasia and Emmanuel Guindon

Long-Term Cost Effectiveness of Oral Semaglutide Versus Empagliflozin and Sitagliptin for the Treatment of Type 2 Diabetes in the Swedish Setting pp. 343-354

Björn Eliasson, Åsa Ericsson, Adam Fridhammar, Andreas Nilsson, Sofie Persson and Barrie Chubb

A Cost-Utility Analysis of Trabecular Bypass Devices Versus Usual Care for Patients With Open-Angle Glaucoma pp. 355-365

Paul R. Healey, Dominic Tilden, Dan Jackson and Lara Aghajanian

Health State Utilities for Adverse Events Associated with Chimeric Antigen Receptor T-Cell Therapy in Large B-Cell Lymphoma pp. 367-376

Timothy A. Howell, Louis S. Matza, Monika P. Jun, Jacob Garcia, Annette Powers and David G. Maloney

Cost Effectiveness of Digital Interventions for Generalised Anxiety Disorder: A Model-Based Analysis pp. 377-388

Dina Jankovic, Pedro Saramago Goncalves, Lina Gega, David Marshall, Kath Wright, Meena Hafidh, Rachel Churchill and Laura Bojke

An Economic Evaluation Supported by Qualitative Data About the Patient Concerns Inventory (PCI) versus Standard Treatment Pathway in the Management of Patients with Head and Neck Cancer pp. 389-403

Victory ‘Segun Ezeofor, Llinos Haf Spencer, Simon N. Rogers, Anastasios Kanatas, Derek Lowe, Cherith J. Semple, Jeffrey R. Hanna, Seow Tien Yeo and Rhiannon Tudor Edwards

Prevalence and Cost of Care for Parkinson’s Disease in Luxembourg: An Analysis of National Healthcare Insurance Data pp. 405-414

Susanne Schmitz, Michel Vaillant, Christell Renoux, Robert L. Konsbruck, Pierre Hertz, Magali Perquin, Lukas Pavelka, Rejko Krüger and Laetitia Huiart

Epidemiologic and Economic Analysis of Rapid Antiretroviral Therapy Initiation with Bictegravir/Emtricitabine/Tenofovir Alafenamide in Spain pp. 415-424

Vicente Estrada, Miguel Górgolas, José A. Peña, Elena Tortajada, Antonio Castro, María Presa and Itziar Oyagüez

Examining the Association between Polish Migrant Status and Health Preferences Using a Novel Application of a Smaller Design EQ-5D-5L Valuation Study pp. 425-435

Dan Kelleher, Samer Kharroubi, Edel Doherty, Gianluca Baio and Ciaran O’Neill

Cost-Effectiveness of Constraint-Induced Movement Therapy Implementation in Neurorehabilitation: The ACTIveARM Project pp. 437-450

Lauren J. Christie, Nicola Fearn, Annie McCluskey, Meryl Lovarini, Reem Rendell and Alison Pearce

Cost Savings of Mother’s Own Milk for Very Low Birth Weight Infants in the Neonatal Intensive Care Unit pp. 451-460

Tricia J. Johnson, Aloka L. Patel, Michael E. Schoeny and Paula P. Meier

Stage-Related Cost of Treatment of Bladder Cancer in Brazil pp. 461-468

Fernando Korkes, Frederico Timóteo, Luiza C. B. Soledade, Lara S. Bugalho, Guilherme A. Peixoto, Vanessa D. Teich and Sidney Glina

Volume 6, issue 2, 2022

Impact of a New Cost-Effectiveness Threshold Implementation on Cancer Formulary Decisions in Jordan pp. 137-145

Imad Treish, Abeer Al Rabayah, Saad Jaddoua and Haitham Tuffaha

Evaluation of Advanced Therapy Medicinal Products by the National Institute for Health and Care Excellence (NICE): An Updated Review pp. 147-167

Ana-Catarina Pinho-Gomes and John Cairns

Budget Impact of the Vest™ High Frequency Chest Wall Oscillation System for Managing Airway Clearance in Patients with Complex Neurological Disorders: A US Healthcare Payers’ Perspective Analysis pp. 169-178

Amir Ansaripour, Kari Roehrich, Atefeh Mashayekhi, Mwanamisi Wanjala, Shani Noel, Mohsen Rezaei Hemami, Angela Murray and Mehdi Javanbakht

Cost Effectiveness of Internet-Delivered Acceptance and Commitment Therapy for Patients with Severe Health Anxiety: A Randomised Controlled Trial pp. 179-192

Bettina Wulff Risør, Ditte Hoffmann Frydendal, Marie Konge Villemoes, Camilla Palmhøj Nielsen, Charlotte Ulrikka Rask and Lisbeth Frostholm

Examining Ways to Improve Weight Control Programs’ Population Reach and Representativeness: A Discrete Choice Experiment of Financial Incentives pp. 193-210

Wen You, Yuan Yuan, Kevin Boyle, Tzeyu L. Michaud, Christopher Parmeter, Richard W. Seidel and Paul A. Estabrooks

Cost of Illness in Patients with Duchenne Muscular Dystrophy in Portugal: The COIDUCH Study pp. 211-218

Pedro Labisa, Valeska Andreozzi, Melina Mota, Susana Monteiro, Rita Alves, João Almeida, Björn Vandewalle, Jorge Felix, Katharina Buesch, Hugo Canhão and Igor Beitia Ortiz de Zarate

Delineating the Type 2 Diabetes Population in the Netherlands Using an All-Payer Claims Database: Specialist Care, Medication Utilization and Expenditures 2016–2018 pp. 219-229

Rose J. Geurten, Jeroen N. Struijs, Arianne M. J. Elissen, Henk J. G. Bilo, Chantal Tilburg and Dirk Ruwaard

Time Trade-Off Utilities for Hereditary Angioedema Health and Caregiver States pp. 231-239

Siu Hing Lo, Andrew Lloyd, Shuayb Elkhalifa, Zlatko Sisic and Floortje E. Nooten

Cost Effectiveness of Durvalumab in Unresectable Stage III NSCLC: 4-Year Survival Update and Model Validation from a UK Healthcare Perspective pp. 241-252

Will Dunlop, Marjolijn Keep, Peter Elroy, Ignacio Diaz Perez, Mario J. N. M. Ouwens, Tina Sarbajna, Yiduo Zhang and Alastair Greystoke

Budget Impact Analysis of an Epigenetic Test Used for Diagnosing Fetal Alcohol Spectrum Disorder from the Perspective of a Laboratory Budget Holder in Manitoba, Canada pp. 253-263

Patrick Berrigan, Geoffrey G. Hicks, Wendy J. Ungar and Jennifer D. Zwicker

The Societal Economic Impact of Secukinumab in First-Line Treatment of Moderate to Severe Plaque Psoriasis in Germany: An Open-Cohort Simulation pp. 265-275

Ahmed H. Seddik, Nima Melzer, Foteini Tsotra and Dennis A. Ostwald

Cost-Effectiveness Analysis of Evolocumab for the Treatment of Dyslipidemia in the Kingdom of Saudi Arabia pp. 277-291

Ahmed Alghamdi, Bander Balkhi, Abdulaziz Altowaijri, Nasser Al-shehri, Lewis Ralph, Emily-Ruth Marriott, Michael Urbich, Fawaz Aljanad and Rima Aziziyeh

Real-World Treatment Patterns, Outcomes, Resource Utilization and Costs in Treatment-Resistant Major Depressive Disorder: PATTERN, a Retrospective Cohort Study in Belgium pp. 293-302

B. Gillain, G. Degraeve, T. Dreesen, G. De Bruecker, E. Buntinx, D. Beke, C. Kestens, E. Valassopoulou, F. Verhelst, E. Peeters, S. Pype, C. De Vos, D. Strens and I. Vandersmissen

Healthcare Costs for Metastatic Castration-Resistant Prostate Cancer Patients Treated with Abiraterone or Enzalutamide pp. 303-313

Dikshyanta Rana, Claudia Geue, Kelly Baillie, Jiafeng Pan, Tanja Mueller, Jennifer Laskey, Marion Bennie, Julie Clarke, Robert J. Jones, Ailsa Brown and Olivia Wu

Volume 6, issue 1, 2022

NICE and the EQ-5D-5L: Ten Years Trouble pp. 5-8

Christopher Sampson

A Systematic Review of Cost-Effectiveness Analyses for Hepatocellular Carcinoma Treatment pp. 9-19

Sydney C. Yuen, Adaeze Q. Amaefule, Hannah H. Kim, Breanna-Verissa Owoo, Emily F. Gorman and T. Joseph Mattingly

The Utility of Economic Measures to Quantify the Burden of Tinnitus in Affected Individuals: A Scoping Review pp. 21-32

Elza Daoud, Charlotte Caimino, Michael A. Akeroyd, Arnaud J. Noreña and David M. Baguley

Cost-Effectiveness Analysis of the Treatment Strategies with or without Opioid Medications in Surgery-Eligible Patients with Osteoarthritis in Japan pp. 33-45

Tomoyuki Takura, Akira Yuasa, Naohiro Yonemoto, Sven Demiya, Hiroyuki Matsuda, Nozomi Ebata, Koichi Fujii and Muneaki Ishijima

Cost-Effectiveness of Inotuzumab Ozogamicin Compared to Standard of Care Chemotherapy for Treating Relapsed or Refractory Acute Lymphoblastic Leukaemia Patients in Norway and Sweden pp. 47-62

I. Oostrum, T. A. Russell-Smith, M. Jakobsson, J. Torup Østby and B. Heeg

A Real-World Assessment of Outcomes, Health Resource Utilization, and Costs Associated with Cerebral Edema in US Patients with Large Hemispheric Infarction pp. 63-72

Nicole Tsao, Qiang Hou, Shih-Yin Chen and Steven R. Messe

Continuous Monitoring of Respiratory Rate with Wearable Sensor in Patients Admitted to Hospital with Pneumonia Compared with Intermittent Nurse-Led Monitoring in the United Kingdom: A Cost-Utility Analysis pp. 73-83

Mehdi Javanbakht, Maziar Moradi-Lakeh, Atefeh Mashayekhi and Jowan Atkinson

Cost Effectiveness of a Cultural Physical Activity Intervention to Reduce Blood Pressure Among Native Hawaiians with Hypertension pp. 85-94

Ashley F. Railey, Clemma Muller, Carolyn Noonan, Maureen Schmitter-Edgecombe, Ka’imi Sinclair, Corin Kim, Mele Look and J. Keawe‘aimoku Kaholokula

Economic Model to Evaluate the Cost-Effectiveness of Second-Line Nilotinib Versus Dasatinib for the Treatment of Philadelphia Chromosome-Positive Chronic Myeloid Leukemia (CML-CP) in Italy pp. 95-104

Massimiliano Bonifacio, Vikalp Maheshwari, Diana Tran, Gianluca Agostoni, Kalitsa Filioussi and Ricardo Viana

Patient and Caregiver Health State Utilities in Tuberous Sclerosis Complex pp. 105-121

Siu Hing Lo, Jade Marshall, Hanna Skrobanski and Andrew Lloyd

Economic Analysis of the CADScor System for Ruling Out Coronary Artery Disease in England pp. 123-135

Mehdi Javanbakht, Atefeh Mashayekhi, Mohsen Rezaei Hemami‬, Michael Branagan-Harris and Eoin Moloney